A Holmes doc beat Clayface, and DC should read the memo

Who expected the scariest thing at the Halloween box office to be a Theranos documentary? Not Gotham's resident shapeshifter, apparently. Clayface, the body horror entry in the DCU, finished second domestically, beaten by Nathan Fielder and Lance Oppenheim's You Can See Everything by the slimmest of margins.

The numbers, as Mercury News reports: the Elizabeth Holmes documentary took $10.6 million in its third weekend, and Clayface trailed by just $200,684 in its second, after a 57% drop. The weekend was sleepy overall, with the total not expected to pass $56 million, which would make it the second-lowest of the year. The figures are estimates until Monday, so the order could still shift.

A documentary is playing like an event, and that's the lesson

Here's what matters: this is the first time the A24 film has hit No. 1. It got there by growing, not by exploding out of the gate. According to IGN, it started on 855 theaters, saw an increase in its second weekend, and dropped only 43% this time. That is the curve of a movie people are telling each other they have to see.

We think that's the real story of the weekend. Word of mouth is hard to buy, and a well-reviewed, specific, conversation-starting film can still make theaters feel like a destination. Meanwhile, the superhero label no longer seems to guarantee that urgency. Clayface is a perfectly reasonable October release, yet it looks like a movie people see once and move on from.

Let's not overdo the thesis, though. A documentary winning a quiet weekend doesn't mean capes are dead. It means the capes now have to compete on the same terms as everything else: a clear hook and a reason to go this weekend, not next month on a screen at home.

Clayface isn't a flop, but it isn't a victory lap either

Fairness first. Clayface is comfortably first worldwide this weekend, and its global total stands at $82.9 million, according to IGN, against a believed $44 million production budget. Domestically it sits at $44.1 million, roughly level with that budget. Add a 7/10 from IGN's review and a modest price tag, and this is a movie that should end up fine, and probably profitable once the weeks ahead add to the total.

But a 57% second-weekend fall for a Halloween-timed horror film is not the sound of a breakout. In our view, the body horror pitch was the right instinct, and the budget was the right size for it. What it didn't create was a must-see moment.

What this means for DC Studios

This is where DC Studios should pay attention. IGN notes the DCU already suffered setbacks when Supergirl failed to follow up on 2025's Superman. In that context, a genre-first, mid-budget bet like Clayface looks like the right kind of correction to us: smaller price tags, a distinctive tone, less dependence on shared-universe homework.

The risk is that "solid and contained" becomes the ceiling. A universe needs at least one release that audiences feel they must attend, not merely approve of. Clayface suggests the lower-budget strategy protects the downside. It doesn't yet show it can raise the upside.

Verdict

Don't read the weekend as a DC disaster, and don't read it as proof that the documentary is the new blockbuster. Read it as a reminder that audiences reward a clear identity and a conversation. If DC can pair its smaller, stranger bets with that kind of specificity, Clayface will look like a useful stepping stone. If not, it will be the movie that lost a Halloween weekend to a Theranos story, and that will be a hard line to live down.